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The nuclear factor y (NF-Y) trimer and TFIID contain
histone fold subunits, and their binding to the CCAAT
and Initiator elements of the major histocompatibility
complex class II Ea promoter is required for transcrip-
tional activation. Using agarose-electrophoretic mobil-
ity shift assay we found that NF-Y increases the affinity
of holo-TFIID for Ea in a CCAAT- and Inr-dependent
manner. We began to dissect the interplay between
NF-Y- and TBP-associated factors PO1II (TAFIIs)-con-
taining histone fold domains in protein-protein interac-
tions and transfections. hTAFII20, hTAFII28, and
hTAFII18-hTAFII28 bind to the NF-Y B-NF-YC histone
fold dimer; hTAFII80 and hTAFII31-hTAFII80 interact
with the trimer but not with the NF-YB-NF-YC dimer.
The histone fold 2 helix of hTAFII80 is not required for
NF-Y association, as determined by interactions with
the naturally occurring splice variant hTAFII80. Ex-
pression of hTAFII28 and hTAFII18 in mouse cells signif-
icantly and specifically reduced NF-Y activation in
GAL4-based experiments, whereas hTAFII20 and
hTAFII135 increased it. These results indicate that NF-Y
(i) recruits purified holo-TFIID in vitro and (ii) can as-
sociate multiple TAFIIs, potentially accommodating dif-
ferent core promoter architectures.
Gene expression is regulated by promoter and enhancer el-
ements recognized by gene-specific DNA-binding proteins and
by general transcription factors (1). At a higher level, it is
controlled by chromatin structures, whose fundamental unit is
the nucleosome, a complex formed by core histones H2A, H2B,
H3, H4, which wrap around them 146 base pairs of DNA (2, 3).
Histones all share a conserved 65-amino acid histone fold motif
(HFM)1 that has low sequence identity but high structural
resemblance (4). Crystallographic analysis showed that this
motif is composed of three/four -helices separated by short
loops/strand regions; this structure enables histones to dimer-
ize and form non-sequence-specific interactions with DNA (5).
Proteins containing the HFM are also involved in the basic
mechanisms of transcription: (i) the two subunits of the TBP-
binding NC2, also called Dr1/DRAP1, a global repressor of
basal transcription (6, 7); (ii) some of the TBP-associated fac-
tors that are part of the TFIID, P/CAF, STAGA, and TFTC
complexes (8–17); (iii) one subunit of the P/CAF complex (18);
and (iv) two subunits of the CCAAT-binding activator NF-Y
(19–21).
TFIID is a general transcription complex composed of TBP,
responsible for TATA recognition, and of several associated
factors, TAFIIs, that constitute a link between gene-specific
upstream activators and the general transcription machinery
by recognizing TATA and/or initiator elements (reviewed in
Refs. 22, 23). Some of the TAFIIs appear to be present in
specific sub-complexes of TFIID (24–33); 10–12 highly con-
served subunits have been identified in yeast, Drosophila, and
human and biochemically characterized in protein-binding as-
says and functional in vitro transcription experiments. Based
on sequence homology, structure-function analysis, and crys-
tallographic studies, hTAFII80/dTAFII60, hTAFII31/dTAFII40,
hTAFII28/dTAFII27, and hTAFII18/dTAFII30 have histone-like
structures (13, 15); hTAFII20/hTAFII135 and hTAFII30 have
also been included in this class (10, 11, 16, 17). Interestingly,
gene inactivation of HFM-containing TAFIIs in yeast impli-
cates them in a rather broad, if not universal, role in transcrip-
tional activation (34–38). This is unlike other TAFIIs, whose
inactivation in yeast suggests a more selective role in certain
promoters (38–40).
Another protein containing HFMs is NF-Y, also termed CBF,
the ubiquitous trimeric protein binding to the widespread
CCAAT-box promoter element; it is composed of NF-YA, NF-
YB, and NF-YC, all necessary for subunit association and DNA
binding (reviewed in refs. 19 and 21). The H2B-H2A-like NF-
YB-NF-YC subunits dimerize tightly via their HFMs, forming a
complex surface necessary for NF-YA association. The result-
ing trimer has a high affinity and sequence specificity for the
CCAAT sequence. Several types of indications link TFIID to
NF-Y. First, their binding sites are either ubiquitous, in the
case of TFIID, or quite frequent, because 25% of the promoters
have NF-Y sites; both are found at highly conserved positions
within a prototypical promoter (20). Second, biochemical evi-
dence of direct interactions has emerged: (i) NF-YB and NF-YC
bind to TBP through short subdomains within the larger yeast/
human conserved parts and short basic residues in the HS2 of
TBP (41); (ii) NF-YB is immunoprecipitated with an anti-
TAFII100 antibody from crude nuclear extracts and is present
in immunopurified TFIID fractions and in high molecular
weight complexes in glycerol gradient experiments, indeed sug-
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gesting association with additional proteins; (iii) the Q-rich
regions of NF-YA and NF-YC interact with dTAFII110 in vitro
(42), a result consistent with the idea that Q-rich activators
such as SP1 and cAMP-response element-binding protein func-
tion by binding to dTAFII110-hTAFII135 (43–48). Third, the
lack of NF-Y binding has been associated with a closed chro-
matin configuration of the Xenopus HSP70 TATA-box region
(49) and, very recently, with the inability to recruit TBP-TFIIB
on the -globin promoter in vivo (50): These results clearly
imply that NF-Y binding is essential for TFIID recruitment.
To study the NF-Y-TFIID connections, we employed the
mouse MHC class II Ea promoter system (51, 52). Ea is a
tissue-specific promoter active in B lymphocytes and other
professional antigen-presenting cells (53). Like all other MHC
class II promoters, it also requires the ubiquitous trimer RFX
and lacks a functional TATA-box. We showed that TFIID bind-
ing to the Ea Inr is necessary for function in an in vitro
transcription system. In this study, we began to dissect NF-Y-
TFIID interplay with purified holo-TFIID, recombinant NF-Y,
and isolated TAFIIs.
MATERIALS AND METHODS
Production and Purification of Recombinant NF-Y, hTAFII31,
hTAFII80, hTAFII28, hTAFII18, hTAFII20, hTAFII1351–372, and holo-
TFIID—Production and purification of recombinant NF-Y trimer were
as described before, using wt NF-YA, wt NF-YB, and a TRX-His-NF-YC
fusion protein (54). Recombinant His-tagged hTAFII28 and hTAFII18,
GST-hTAFII28 (9), GST-hTAFII1351–372 (12), and GST-hTAFII20 (9)
were produced in Escherichia coli as soluble proteins and purified
according to standard procedures. hTAFII31, hTAFII80, and hTAFII80
were produced by the baculovirus expression system, either as single
subunits or as a dimer, using standard protocols and purified to homo-
geneity. hTAFII80 contains a FLAG tag. Holo-TFIID was immunopuri-
fied from HeLa cells with an anti-TBP antibody as previously detailed
(9, 26, 27).
EMSA Analysis—EMSAs of TFIID in agarose gels were as described
in Ref. 52: holo-TFIID fractions were incubated in NF-Y buffer (20 mM
HEPES, pH 7.9, 50 mM NaCl, 5% glycerol, 5 mM MgCl2, 1 mM dithio-
threitol) together with 10,000 cpm of 32P-labeled Ea fragments; the
total volume was 10 l. After incubation for 45 min at 30 °C, we added
2 l of 1 buffer containing bromphenol blue, and samples were loaded
on a 1.5% agarose gel (Bio-Rad Ultrapure) in 0.5 TBE. Gels were run
at 140 V for 90 min at 4 °C, transferred onto DE81 paper, vacuum-
dried, and exposed. Three independent preparations of purified TFIID
were used in EMSAs. The Ea fragments used in EMSA analysis were
obtained by PCR and contained sequences from 115 to 60 of the Ea
promoter, either wt, mutated in the Y box (Ls17 (51)), or in the Inr (Ls21
(52)).
Antibodies and Supershift EMSA—For supershift experiments, anti-
NF-YA and -NF-YB antibodies were purified on antigen columns (55).
Monoclonal antibodies against TAFIIs were as follows: 24TA and 26TA,
anti-hTAFII80; 22TA, anti-hTAFII20; 15TA, anti-hTAFII28; and 16TA,
anti-hTAFII18 (9, 12, 26). Monoclonal antibodies were purified by ca-
prylic acid precipitation of ascites fluid followed by precipitation with
50% ammonium sulfate, resuspension in phosphate-buffered saline,
and dialysis against NDB100 (100 mM KCl, 20 mM HEPES, pH 7.9, 20%
glycerol, 0.5 mM EDTA). The hTAFII31 rabbit polyclonal was a kind gift
of Dr. A. Levine. Supershift experiments were performed by preincu-
bating TFIID, with or without NF-Y, with the indicated antibodies (200
ng of purified monoclonal antibodies, 0.3 l of the anti-hTAFII31 poly-
clonal, 200 ng of purified anti-NF-YA and anti-YB) for 2 h on ice, before
addition of the labeled DNA and further incubation at 30 °C for 45 min.
Protein-Protein Interactions—Interactions with NTA-agarose col-
umns were performed by incubating either crude bacterial extracts or
purified His-tagged proteins (1 or 2 g) in BC100 (100 mM KCl, 20 mM
HEPES, pH 7.9, 10% glycerol, 5 mM imidazole, 5 mM -mercaptoetha-
nol) with NTA-agarose (100–200 l); the column was washed with
BC300 and BC1000, containing 300 mM and 1 M KCl, respectively;
proteins were eluted in BC100 buffer containing 300 mM imidazole,
dialyzed against BC100, and assayed in Western blots. Immunoprecipi-
tations were performed as follows: The NF-Y trimer (500 ng) and an
equivalent amount of the indicated TAFIIs were added to 25 l of
Protein G-Sepharose to which 7.5 g of the purified anti-NF-YA7 mono-
clonal antibody had been previously bound. Incubation was pursued for
2 h on ice, unbound material was recovered after centrifugation, and the
beads were washed with NDB100 with the addition of 0.1% Nonidet
P-40. SDS buffer was added, and the samples were boiled at 90 °C for 5
min and loaded onto SDS gels. Western blots were performed according
to standard procedures with the indicated primary antibody and a
Pierce peroxidase secondary antibody. For multiple interactions, the
filter was stripped, blocked with nonfat dry milk, and re-hybridized.
Transfections—The eukaryotic expression vectors for NF-Y,
hTAFII28, hTAFII18, hTAFII20, hTAFII135, and hTAFII80 were de-
scribed before (9, 12, 56). From PCR-hTAFII31 (kindly donated by
Dr. Levine) an EcoRI insert was cloned into pGAL4poly in-frame with
the Gal4 DNA-binding domain, and the latter was excised by cutting
with XhoI and a partial EcoRI digest. Mouse NIH-3T3 fibroblasts were
co-transfected with 1–3 g of activating plasmids, 2 g of the plasmids
containing the Luciferase reporter gene, and 3 g of pNGal plasmid for
control of transfection efficiency. The total amount of DNA was kept
constant (at 15 g) with Bluescript. All plasmids were purified by
centrifugation using cesium chloride gradients. Cells were transfected
with the standard calcium-phosphate method, recovered 48 h after
transfection, washed in phosphate-buffered saline (150 mM NaCl, 10
mM sodium phosphate, pH 7.4), and resuspended in the Reporter assay
reagent (Promega). Luciferase and -galactosidase activity were meas-
ured according standard procedures. A minimum of three independent
transfections in duplicate was done; most of the values are based on
8–12 transfections.
RESULTS
Binding of NF-Y and TFIID to the Ea Promoter—We have
previously shown that the MHC class II Ea promoter is cru-
cially dependent on a binding of holo-TFIID to a TdT-like
initiator (52). We investigated the interactions between NF-Y
and holo-TFIID in such a system using recombinant NF-Y and
immunopurified holo-TFIID in agarose-EMSA. Fig. 1 (A and B)
shows a dose response of TFIID either alone (lanes 5–7), or with
a fixed amount of NF-Y (lanes 2–4): in Fig. 1A the NF-Y dose
saturated the labeled fragment (lane 1), whereas in Fig. 1B
lower doses of NF-Y were used. Two major complexes of differ-
ent mobility, termed IIDa and IIDb, were generated by TFIID;
when incubated with NF-Y, both complexes generated dissim-
ilar electrophoretic mobilities, clearly arising as a result of
co-incubation of NF-Y and TFIID (Fig. 1A, compare lanes 2–4
with 5–7; Fig. 1B, compare lanes 1–3 with 5–7): One complex
migrated slightly more slowly than the NF-Y band, and an-
other was further retarded and visible at higher TFIID concen-
trations. Note that the upper Y/IID complexes were visible at
lower TFIID concentrations (Fig. 1A, compare lanes 3 and 6).
As a control for the specificity of the interactions, we used an
identical Ea fragment carrying a 10-bp mutation in the Y-box,
known to abolish NF-Y binding, as well as in vivo and in vitro
transcriptional activity of the promoter (51): As expected, bind-
ing of NF-Y, but not TFIID, was abolished, and the upper bands
resulting from simultaneous interactions were not detected
(Fig. 1C).
To verify the effect of TFIID on NF-Y binding, a reciprocal
experiment was also performed, namely a dose-response anal-
ysis of NF-Y alone, or with two TFIID concentrations (Fig. 1, D
and E, lanes 2–7). The TFIID pattern at high concentrations
was clearly modified in a dose-dependent manner by NF-Y (Fig.
1D, compare lanes 1 with 2–4). Interestingly, the lowest
amount of NF-Y employed (0.1 ng), which was barely sufficient
to generate a visible band, modified the pattern of the TFIIDa
and -b bands. When incubated with low amounts of TFIID,
insufficient to shift Ea DNA, the NF-Y band was evident at
lower concentrations (Fig. 1E, compare lanes 2 and 3 with 6
and 7). In experiments conceptually similar to those of Fig. 1C,
we employed a fragment containing a 10-bp mutation in the Ea
Inr region, known to cripple TFIID binding and Ea promoter
function in vitro (52): The NF-Y complex, but not the TFIID or
the Y/IID complexes, was generated by co-incubation of the two
proteins (Fig. 1F), indicating that an intact Inr is required for
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the formation of the NF-Y-TFIID complexes.
Next, we wished to determine whether the Y/IID complexes
observed in our EMSAs truly contain TAFIIs. To this aim, we
used antibodies specific for different TAFIIs in supershift ex-
periments. Fig. 1G indicates that anti-hTAFII31, anti-
hTAFII30, anti-hTAFII20, and two different anti-hTAFII80 an-
tibodies all modify the Y/IID complexes, whereas an irrelevant
anti-GATA1 antibody had no effect (Fig. 1G, upper panel, com-
pare lanes 1 and 2 with 3–7). In parallel, when challenged with
the IIDa complex, these antibodies all showed interactions
(Fig. 1G, middle panel), whereas none recognized the NF-Y
complex (Fig. 1G, lower panel). Note that the anti-hTAFII31
antibody, rather than supershifting the IIDa or Y/IID com-
plexes, apparently inhibited binding of TFIID to DNA. Finally,
we verified whether the Y/IID complexes also contain NF-Y, by
challenging them with anti-NF-YA and anti-NF-YB antibodies.
Indeed, both antibodies modified the mobilities of the com-
plexes (Fig. 1H). The experiments shown in Fig. 1 (A–E) also
suggest that the presence of NF-Y improves the binding capacity
of holo-TFIID. We verified whether NF-Y can facilitate binding of
TFIID by performing on-rate experiments: Binding of TFIID to
DNA, in fact, is known to be a slow process, and the on-rates even
on high affinity TATA-Inr elements are on the order of 20–40
min (Ref. 57, and references therein). On the contrary, NF-Y
FIG. 1. EMSA analysis of NF-Y and holo-TFIID binding to Ea core sequences. A, dose-response analysis of holo-TFIID in the presence
(lanes 2–4) or absence of 1 ng of NF-Y (lanes 2–4, 0.2, 1, 3 l, respectively); in lane 1, 1 ng of NF-Y was used. B, same as in A, except that a low
amount of NF-Y (0.1 ng) was used in each of lanes 5–8. No protein was added in lane 1. C, dose response of NF-Y (0.1 ng in lanes 2, 5, 8, 11; 0.3
ng in lanes 4, 6, 9, 12) with (lanes 4–6, 10–12) or without (lanes 1–3, 7–9) 1 l of TFIID. The wt Ea 90/60 promoter fragment was used in lanes
1–6, whereas in lanes 7–12 we used a fragment of identical length containing a 10-bp mutation in the CCAAT box (LS17 (see Ref. 51)). D, dose
response of NF-Y (0.01, 0.1, 1 ng, lanes 2–4 and 5–7, respectively) were incubated alone (lanes 2–4) or with 3 l of TFIID (lanes 6–8). E, same as
in D, except that 0.3 l of TFIID was used. F, dose response of NF-Y (0.1 ng in lanes 2, 5, 8, 11; 0.3 ng in lanes 4, 6, 9, 12) with (lanes 4–6, 10–12)
or without (lanes 1–3, 7–9) 0.3 l of TFIID. In lanes 1–6 we used the wt Ea90/60 promoter fragment; in lanes 7–12 a fragment of identical length
containing a 10-bp mutation in the Initiator (LS21 (see Ref. 52)) was used. G, antibody supershift of NF-Y/TFIID, TFIID, and NF-Y complexes: the
indicated antibodies (anti-hTAFII80 monoclonals were 24TA in lanes 6 and 26TA in lanes 7) were incubated with TFIID on ice before addition of
NF-Y (upper panel), with TFIID alone (middle panel), and with NF-Y (lower panel). For details of the antibodies, see “Materials and Methods.” The
control antibody was an anti-GATA1 monoclonal. H, supershift experiments as in C, with anti-NF-YB (lane 2)- and anti-NF-YA (lane 3)-purified
polyclonal antibodies.
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binding under our experimental conditions is extremely rapid,
being completed after 1–2 min (Fig. 2A; see also Ref. 58). We
incubated suboptimal amounts of TFIID (see Fig. 1E) with and
without saturating amounts of NF-Y: A weak IID band was seen
only after 30 min of incubation in the absence of NF-Y (Fig. 2B,
lanes 6–9), whereas the upper Y/IID complexes were evident
already after 2 min of incubation at 30 °C, and maximal after 5
min (Fig. 2B, lanes 2 and 3), strongly suggesting that NF-Y-
CCAAT complexes recruit TFIID onto the Ea initiator.
From this set of in vitro experiments with purified holo-
TFIID and recombinant NF-Y, we conclude that: (i) complexes
of different mobilities are formed upon simultaneous binding of
TFIID and NF-Y to the Ea promoter; (ii) these complexes con-
tain both TAFIIs and NF-Y; (iii) binding of NF-Y to the CCAAT
box and of TFIID to the initiator is required; and (iv) TFIID
binding is remarkably facilitated when NF-Y is bound to DNA.
Binding of NF-YB-NF-YC to Histone Fold TAFIIs—A large
number of subunits are present in holo-TFIID, and full recon-
stitution of the holo-TFIID complex with recombinant proteins
has not been achieved yet. We therefore decided to dissect
NF-Y-TFIID interactions by taking a reductionist approach,
investigating the interactions between isolated HFM subunits
of the two complexes. Recombinant proteins were produced in
E. coli or Baculovirus and purified (Fig. 3). Note that the
GST-hTAFII1351–372 protein used hereafter is a mutant con-
taining the C-terminal region with the HFM (16) but lacking
the N-terminal 372 Q-rich region that mediates binding to
Q-rich activators, such as SP1 and cAMP-response element-
binding protein (46), and possibly contact NF-Y (42). The
recombinant NF-YB-NF-YC dimer, containing the histone
folds, was incubated with bacterial extracts containing GST-
hTAFII28, GST-hTAFII1351–372, GST-hTAFII20, or GST-
hTAFII20-GST-hTAFII1351–372, and Sf9 extracts containing
hTAFII80-hTAFII31. The complexes were purified over a nickel
NTA-agarose column, exploiting the presence of His tags on
NF-YC. Columns were washed with buffers containing 0.3 M
and 1 M KCl, and eluted with 0.3 M imidazole. Flow-through,
wash, and bound material were checked in Western blots with
the respective antibodies. Results of the experiments are
shown in Fig. 4. As expected, NF-YB was efficiently bound to
the column, despite the lack of His tags (Fig. 4, upper panels).
GST-hTAFII20 and GST-hTAFII28 were efficiently retained on
the columns but were in the FT fraction in the absence of
NF-YB-NF-YC, thus ruling out that any of the HFM proteins
tested had any intrinsic affinity for NTA-agarose (Fig. 4 and
data not shown). On the other hand, GST-hTAFII1351–372,
GST-hTAFII20-GST-hTAFII1351–372, and hTAFII80-
hTAFII31 were not retained by the affinity column. The re-
verse approach was also tested, namely His-tagged hTAFII28,
hTAFII18, and hTAFII18-hTAFII28 were incubated with an
NF-YB-NF-YC5 dimer lacking His tags. In this experiment,
we used an NF-YC mutant, YC5, that contains only the
evolutionarily conserved part of NF-YC, fully capable to as-
sociate NF-YB. The NF-Y HFM subunits were found in the
bound fractions with hTAFII28 and hTAFII18-hTAFII28 but
not with hTAFII18.
From this set of experiments we conclude that only
hTAFII28, hTAFII18-hTAFII28, and hTAFII20, but not the
HFM containing hTAFII20-hTAFII1351–372, nor hTAFII80-
hTAFII31, are capable to associate the NF-Y HFM dimer in
solution.
Binding of NF-Y to Histone Fold TAFIIs—Because NF-YA is
necessary for CCAAT-box binding and is known to recognize
determinants in the HFMs of both NF-YB and NF-YC (19), it
was important to test whether the interactions with TAFIIs
would also be scored in the context of the trimeric complex.
NF-YA has an intrinsic affinity for NTA-agarose and is unsuit-
able for the protein-protein interaction approach taken above,
most likely because of the high number of His residues in the
conserved domain (Not shown). We thus switched to immuno-
precipitations with the purified recombinant NF-Y trimer and
the different TAFIIs, either as single subunits or dimers. The
complexes were incubated with Mab7, a monoclonal antibody
that recognizes the NF-YA Q-rich activation domain (55), pre-
viously bound to a Protein G-Sepharose matrix; in parallel,
equivalent amounts of recombinant proteins were incubated
with a control Protein G-Sepharose resin associated with an
irrelevant anti-MHC class II antibody. After washing, bound
material was recovered by boiling samples in SDS buffer and
analyzed in Western blots with the anti-NF-Y and anti-TAFII
antibodies. As expected, NF-YA and NF-YB are immunopre-
cipitated with Mab7 but not with the control antibody (Fig. 5A,
upper panel); the same was true for NF-YC (not shown, see
below). Incubation of NF-Y with hTAFII28, but not with
TAFII18, retained the TAFII in the bound material. Surpris-
ingly, unlike the previous experiments with the NF-YB-NF-YC
dimer, when incubated together with the NF-Y trimer, inter-
actions of the hTAFII28-hTAFII18 dimer were not observed,
implying that the presence of NF-YA prevents hTAFII28-
hTAFII18 binding to the NF-Y HFM dimer. On the other
hand, hTAFII20 and the hTAFII80-hTAFII31 dimer, but not
hTAFII20-hTAFII1351–372, were bound to the NF-Y trimer.
hTAFII80, but not hTAFII31, was immunoprecipitated when
incubated alone with NF-Y. In this experimental setting, we
also used a differentially spliced form of hTAFII80, termed
hTAFII80, in which 10 amino acids of the HFM 2 are missing.
This isoform is incapable of interacting with hTAFII31.
2 We
tested this protein in the immunoprecipitation assays and
found that, as for hTAFII80, it is able to interact with NF-Y. To
confirm that hTAFII20-hTAFII1351–372 and hTAFII28-
hTAFII18 are present in dimeric form in our assays, we immu-
noprecipitated these dimers, in the absence of NF-Y subunits,
with anti-hTAFII135 and anti-hTAFII18 monoclonal antibod-
ies, respectively. Fig. 5B shows that both hTAFII20 and
hTAFII28 are indeed associated with their respective partners,
as assessed in Western blots.
From the immunoprecipitation analysis of the NF-Y trimer, we
conclude that hTAFII18 and hTAFII31 do not bind NF-Y, whereas
2 B. Bell and L. Tora, submitted.
FIG. 2. On-rates of TFIID and NF-Y on the Ea promoter. A,
EMSA on-rate experiments of NF-Y (1 ng). B, same as in A, except that
NF-Y and TFIID (0.1 l) were used. Experiments were performed by
preincubating NF-Y alone (lane 1) for 15 min at RT and then adding
holo-TFIID for the indicated time before loading a running agarose gel
(lanes 2–5). Incubations of TFIID alone for the corresponding times are
shown in lanes 6–9.
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hTAFII80, hTAFII80, hTAFII28, and hTAFII20 are capable of
associating with the trimer. Upon dimerization, hTAFII31-
hTAFII80, but not hTAFII28-hTAFII18, can bind to NF-Y.
Effect of TAFIIs Overexpression on NF-Y Activation in Mam-
malian Cells—Having established that NF-Y is capable of in-
creasing the binding of holo-TFIID and associated multiple
TAFIIs in vitro, we sought to investigate the in vivo effects with
“co-activator” assays used for other activators (12, 59–62). The
system is based on the co-expression in NIH-3T3 fibroblasts of
GAL4-NF-YA together with NF-YB and NF-YC, activating a
promoter containing five GAL4 sites driving the Luciferase
reporter gene: Transcription is strictly dependent upon co-
transfection of all NF-Y subunits, requiring at least one of the
NF-Y Q-rich domains (56; see Fig. 6A). Co-transfections of
different amounts of vectors expressing the TAFIIs used in our
in vitro analysis gave the results outlined in Fig. 6B: hTAFII20
FIG. 3. Purification of recombinant
proteins. SDS gels stained with Coomas-
sie Blue showing the indicated purified
recombinant proteins used for protein-
protein assays. The GST-hTAFII1351–
372 is a mutant lacking the 372 amino
acids at the N-terminal of the protein and
containing the HFM.
FIG. 4. Protein-protein interactions of TAFIIs and NF-Y HFM
subunits. A, in the different panels, wt NF-YB-NF-YC His-tagged were
incubated with GST-hTAFII18 and GST-hTAFII28, before loading onto
NTA-agarose. Load, flow-through, 300 mM, and 1.0 M KCl washes and
the two imidazole-eluted fractions are indicated. The fractions were run
in SDS gels, and the proteins are revealed by Western blotting with the
indicated antibody. Similar experiments are shown for GST-hTAFII20,
GST-hTAFII1351–372, GST-hTAFII20-GST-hTAFII1351–372, and
hTAFII80-hTAFII31. In the lower panels, an NF-YB-NF-YC dimer de-
void of the His tag, consisting of wt NF-YB and of the HFM-containing
YC5 mutant (54), was incubated with the indicated hTAFIIs. From top
to bottom: His-tagged hTAFII28, His-tagged hTAFII18, and hTAFII28-
hTAFII18 (both His-tagged).
FIG. 5. Immunoprecipitations of NF-Y and HFM TAFIIs. A,
equivalent amounts of recombinant NF-Y and the indicated hTAFIIs
were incubated and immunoprecipitated with the anti-NF-YA mono-
clonal antibody 7 (55), or with an anti-MHC class II control antibody.
Load (L), unbound (U), and bound (B) materials were loaded onto SDS
gels and checked in Western blots with the indicated antibody. B,
Western blots of immunoprecipitations of the His-hTAFII18-His-
hTAFII28 dimer with the anti-hTAFII18 antibody 16TA. Similarly,
Western blot analysis of immunoprecipitations of preparations contain-
ing GST-hTAFII20 and GST-hTAFII1351–372 with the 20TA mono-
clonal antibody against hTAFII135.
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and hTAFII135 had small, 2-fold-positive effects on GAL4-
NF-Y activation; hTAFII31 and hTAFII80, either alone or in
combination showed no effect; whereas expression of hTAFII18
and hTAFII28, alone or together, had a clear dose-dependent
negative effect. To verify whether this inhibition was specific
for the NF-Y trimer, or exerted indirectly through the basal
promoter, we tested in similar assays an NF-YA mutant, G4-
YA12, containing the isolated activation domain of NF-YA
fused to the DNA-binding domain of GAL4, and GAL4-SP1,
also a Q-rich activator. Co-expression of hTAFII18 and/or
hTAFII28, or of the other TAFIIs, had minor effects on GAL4-
YA12 or GAL4-SP1 (Fig. 6, C and D): if anything, hTAFII18
and/or hTAFII28 slightly increased GAL4-SP1 activation. Be-
cause the reporter construct was identical in all these experi-
ments, these latter experiments rule out that the strong inhib-
itory effect of hTAFII18-hTAFII28 observed on the GAL4-NF-Y
trimer is due to an unspecific repression of core promoter
activity; moreover, inhibition is specific for the NF-Y trimer
and not for the Q-rich activation domains, such as those of
NF-YA, or of SP1.
DISCUSSION
TFIID Recruitment—The TATA-box is the most frequent
promoter element. When absent, polymerase II positioning is
in general assured by an initiator; i.e. both these core elements
are recognized by TFIID (1). NF-Y binding sites are found in
25% of eukaryotic promoters, invariably playing an important
and sometimes essential role. Both boxes are normally found at
a fixed position, TATA at 25/30 and CCAAT at 60/100.
The mean CCAAT-box position and orientation in TATA and
TATA-less promoters pointed to a small, but significant differ-
ence (20),3 suggesting that the proteins binding to these sites
could directly or indirectly interplay. In keeping with this, we
previously presented biochemical evidence showing that the
NF-Y HFM subunits are associated with holo-TFIID and can
bind TBP directly (41). The aim of our study was to examine
their relationships, using a model system, the MHC class II Ea
promoter, in which the functional importance of the two com-
plexes is well established. We have previously shown, in fact,
that holo-TFIID binds to a TdT-like initiator in the Ea pro-
moter in a sequence-specific way. Our EMSA analysis is the
first indication that NF-Y helps recruit holo-TFIID, thereby
adding experimental proof to the hypothesis that NF-Y and
TFIID have intimate relationships. It should be noted that
other upstream factors are thought to recruit TBP and associ-
ated factors, as an important step in the formation of a tran-
scriptional competent complex (1). Concerning the mechanisms
of such DNA-binding facilitation, an obvious hypothesis is that
there are direct protein-protein contacts between TAFIIs and
NF-Y. We already detailed the binding of NF-YB-NF-YC to
TBP (41), and the in vitro analysis presented here is strongly
supportive of this, because a number of TAFIIs show affinity for
NF-Y. Indeed, the multiple interactions of HFM TAFIIs with
NF-Y observed in solution invite the speculation that TFIID
binding might be influenced, if not dictated, by one or more
transcription factor combinations binding nearby. Interest-
ingly, we evidenced holo-TFIID complexes showing differential
mobilities in our EMSAs, depending on the presence or absence
of NF-Y: The upper TFIIDb, for example, migrates faster with
NF-Y, possibly suggesting that a different composition of sub-
units might be present and that a DNA-bound NF-Y might
select specific sub-complexes. The apparent multiplicity of
TFIID combinations could then reflect into a plasticity of DNA
binding, because the presence of adjacent activators might
select subtypes of holo-TFIIDs with subunit compositions par-
ticularly suited to fit within the context of a given promoter.
Antibody supershifting experiments, although showing that
“core” TAFIIs are present in the IID/Y complexes, cannot yet
provide us with a complete description of the composition of
these complexes.
TFIID is known to be capable of sequence-specific interac-
tions, and multiple subunits within TFIID can contact DNA
(63, 64 and references therein). In the course of our analysis we
found no evidence of sequence-specific binding of the isolated
HFM TAFIIs considered here to the Ea promoter (data not
shown). Non-HFM TAFIIs with well documented core promoter
DNA-binding specificity, such as hTAFII150 and/or hTAFII250
(64), could then be considered for the Inr-binding activity.
NF-Y Interactions with HFM TAFIIs—Complete reconstitu-
tion of the holo-TFIID complex with recombinant subunits has
not been achieved yet. We therefore dissected NF-Y interac-
tions with individual TAFIIs. Given the common structural
features of many TAFIIs with NF-Y subunits, we decided to
start with HFM TAFIIs. In general, our analysis showed sev-
eral interactions between NF-Y and TAFIIs: Minimally,
hTAFII28, hTAFII80, and hTAFII20 have affinity for either the
HFM NF-YB-NF-YC dimer, the trimer, or both (Table I).
hTAFII135 should be added to this list (42), because the nega-
tive results obtained here probably reflect the absence of the
N-terminal Q-rich region. Therefore, the interactions of the
trimer with hTAFII20 and hTAFII80 are possibly relevant for
the function of the CCAAT-binding trimer. On the other hand,
3 R. Mantovani, unpublished.
FIG. 6. TAFIIs-mediated transcriptional modulation of NF-Y
activity. A, scheme of the GAL4 vectors used in the transfection ex-
periments (56). Black boxes indicate the GAL4 DNA-binding domain;
hatched boxes represent the Q-rich regions; gray boxes the homology
domains. B, NIH-3T3 fibroblasts were transfected with a GAL4-driven
Luciferase reporter and 1 or 3 g of TAFIIs plasmids as indicated. C and
D, same as B, except that GAL-SP1 and GAL4-YA12 (56) were used
with the indicated co-transfected TAFIIs.
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the interactions of hTAFII28-hTAFII18 with the HFM NF-YB-
NF-YC dimer, but not with the trimer, should be considered in
the light of the presence of the HFM dimer, without NF-YA, in
several cell types, including monocytes and differentiated myo-
tubes (21). This finding might point to a role in the basic
mechanisms of activation on promoters that lack the CCAAT
target site.
The HFM TAFIIs are present not only in TFIID but also in
other complexes: (i) hTAFII135, hTAFII80, and hTAFII20 are
found in TFTC, a TAFIIs-containing complex lacking TBP (27,
30); (ii) hTAFII20 and hTAFII31 (and the hTAFII80-like
PAF65) are in the P/CAF complex (18); and (iii) hTAFII31 is
found in STAGA (28). A histone octamer-like structure within
TFIID has been hypothesized (10); indeed, core histones and
hTAFII80, hTAFII31, and hTAFII20 interact through their
HFMs in ways that are consistent with histones rules: The
H4-like hTAFII80 with H3 and H2B, the H3-like hTAFII31 with
H4, and the H2B-like hTAFII20 with H2A and H4. These in-
teractions are fully in agreement with previous findings on the
binding of H3-H4 and H2A-H2B subfamilies of histone folds.
Crystallographic analysis of the nucleosome found details for
residues that are required for H4-H2B interactions: H4 His-75
and H4 Lys-91, and H2B Glu-90 and H2B Glu-73 (5). These
residues are conserved in hTAFII80 and in the related PAF65.
In NF-YB, the Asp-115 and Glu-98 residues corresponding to
H2B Glu-90 and Glu-73 are among the relatively few amino
acids present in all 26 NF-YB sequences from different species
(65). We found that NF-Y is able to interact with an isoform of
hTAFII80-hTAFII80, which lacks 10 amino acids in the 2
helix of the HFM (66), a fact that is mirrored by the interaction
of hTAFII80 with the H2B-like hTAFII20.
4 Under these cir-
cumstances, it is unclear what the structure of the HFM might
be, but the 2 subunit is crucial for the formation of het-
erodimers and, indeed, hTAFII80 is unable to bind to
hTAFII31: Other parts of the HFM might be involved in the
contacts with the H2B-likes. Alternatively, a domain of
hTAFII80 distinct from the HFM might be implicated in con-
tacting NF-Y. Concerning the hTAFII28/hTAFII18 dimer, struc-
tural analysis detailed somewhat different sorts of HMFs not
easily assigned to any of the core histone sub-classes (15). Thus
it is difficult to rationalize our interactions data with available
structural information.
TAFIIs are known to contact the activation domains of gene-
specific upstream factors, and indeed the capacity of a given
factor to activate transcription in vitro correlates well with its
TAFII-binding ability (1). Conditional inactivation of yeast his-
tone fold TAFIIs, yTAFII17/hTAFII31, yTAFII60/hTAFII80, and
yTAFII68/hTAFII20, provided compelling genetic evidence for
their general role in promoter activation (34–38). However,
only a limited set of studies focused on the effect of TAFIIs
overexpression in mammalian cells. In some cases, positive
effects were seen: hTAFII28 on the activation factor 2 of retinoic
X receptor and hTAFII135 on retinoic acid receptor, vitamin D
receptor and thyroid receptor (12, 59). In other reports, in vitro
interactions, SP1-hTAFII135, E1A-hTAFII135, and p53-
dTAFII40-dTAFII60-dTAFII230, were matched by strong re-
pression in co-transfections of the TAFIIs with GAL4 fusions
containing the activation domains (61, 67), although the same
TAFIIs interactions with GAL4-p53 resulted in activation in
vitro (68). In our GAL4 assays, we observe a similar negative
effect by overexpressing hTAFII28 and/or hTAFII18 on the ac-
tivation of the NF-Y trimer. It should be noted that this is
specific, both for the target, it is not seen with GAL4-SP1 and
the Q-rich activation domain of NF-YA, and for these two
TAFIIs, because hTAFII31-hTAFII80 have negligible effects and
hTAFII20-hTAFII135 have small positive effects; moreover,
hTAFII28-hTAFII18 do not inhibit the natural Ea promoter (not
shown). What might be the reason for the inhibition of GAL4-
NF-Y fusions? Our in vitro results indicate that the hTAFII28-
hTAFII18 dimer interacts with NF-YB-NF-YC, but not with the
NF-Y trimer, implying that NF-YA, which recognizes determi-
nants in the HFMs of both subunits (20), prevents the associ-
ation of hTAFII28-hTAFII18 to NF-YB-NF-YC. Because forma-
tion of the trimer in vivo is essential for GAL4-NF-YA
activation (56), one can imagine that the co-transfected TAFIIs
could compete for binding to NF-YA by associating NF-YB-NF-
YC. However, other interpretations must reconcile our findings
that the NF-Y-interacting hTAFII28 and the non-interacting
hTAFII18 both inhibit when transfected alone. It is possible
that overexpression of some TAFIIs alters the stoichiometry of
endogenous TFIID complexes, impairing their capacity to me-
diate activation through the artificial GAL4 constructs. In this
respect, it should be noted that certain mouse tissues do have
with lower amounts of hTAFII28 and hTAFII18 (33).
TAFIIs and MHC Class II Transcription—In addition to
NF-Y, binding the trimeric complex RFX is important for MHC
class II promoters (53). The NF-Y-RFX trimers make coopera-
tive interactions. In particular, NF-Y binding improves the
otherwise rather inefficient binding of RFX. Two non-DNA-
binding co-activators are also crucial: the ubiquitous p300/CBP
(69, 70) and the tissue-specific CIITA (reviewed in Ref. 71). A
network of protein-protein interactions is emerging, in partic-
ular, CIITA can interact with hTAFII31. Our finding that the
hTAFII80-hTAFII31 dimer can associate NF-Y through
hTAFII80 suggests that hTAFII80-hTAFII31 could be contacted
at the same time by two of the MHC class II activators. The
interactions of NF-Y with HFM TAFIIs should be considered in
the light of recent findings showing that both complexes can
associate HATs: p300, P/CAF, and hGCN5 interact with NF-Y
(21), whose NF-YB subunit is acetylated by p300 (72). Simi-
larly, CBP/p300 can interact with CIITA. It has been suggested
that TAFIIs could be chaperones of the histone-modifying ma-
chines in the proximity of core promoters. NF-Y could recruit
acetylase complexes not only through direct interactions with
P/CAF, GCN5, or CBP/p300, but also by contacting P/CAF
complexes, via the HFM TAFIIs. From its privileged location at
60, NF-Y is clearly a pivotal factor at the cross-road of mul-
tiple connections: It helps upstream factors such as RFX on
MHC class II promoters bind DNA, and it recruits TFIID by
binding to TBP and to core TAFIIs. At a higher level, NF-Y
reaches its site efficiently in the context of a pre-formed nu-
cleosome, interfacing well with H3-H4 tetramers (54). In sum-
mary, NF-Y represents an excellent candidate for penetrating
chromatin structures, allowing other upstream activators bind
their sites, organizing TFIID complexes and recruiting co-acti-
vators that further modify, by acetylation, surrounding nucleo-
somes. Studies aimed at clarifying the complexity of NF-Y-4 B. Bell and L. Tora, unpublished.
TABLE I
Summary of NF-Y/TAFII interactions
NF-Y NF-YB-NF-YC
TAFII28  
TAFII18  
TAFII18-TAFII28  
TAFII31  
TAFII80  ND
a
TAFII80-TAFII31  
TAFII20  
TATII1351 –372  
TAFII20-TAFII1351–372  
a ND, not determined.
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TFIID interplay by taking into account the interactions with
other TAFIIs are currently underway.
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